QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer

QIAGEN’s QuantiFERON®-TB passes milestone of 60 million tests in global fight against tuberculosis, current annual run rate exceeds 12 million tests

QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version

QIAGEN highlights profile of new QIAstat-Dx Meningitis / Encephalitis panel focused on most prevalent central nervous system pathogens

QIAGEN and LabCorp launch collaboration to provide Day-One access for patients to innovative companion diagnostics at the time of drug approvals

QIAGEN launches novel liquid biopsy solutions and NGS panels with seamlessly integrated bioinformatics to support advances in cancer research

QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis

QIAGEN and Tecan announce collaboration to streamline preanalytical processing of QuantiFERON-TB Gold Plus

QIAGEN announces 20-F annual report filing for 2018 results

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens